Codexis (NASDAQ:CDXS) Is A Stock That Stephens Seems to be Very Interested In

May 16, 2018 - By Vivian Park

Codexis, Inc. (NASDAQ:CDXS) Logo

Investors sentiment decreased to 2.17 in 2017 Q4. Its down 0.03, from 2.2 in 2017Q3. It worsened, as 3 investors sold Codexis, Inc. shares while 15 reduced holdings. 12 funds opened positions while 27 raised stakes. 28.02 million shares or 9.42% more from 25.60 million shares in 2017Q3 were reported.

First Light Asset Management Limited Liability Co stated it has 804,224 shares or 1.84% of all its holdings. Prescott Group Incorporated Management Ltd Liability Company reported 2.13M shares stake. Blair William & Com Il holds 149,247 shares or 0.01% of its portfolio. Royal Bank & Trust Of Canada has 42,147 shares. National Bank Of Montreal Can accumulated 1,324 shares. Barclays Public Ltd Co has invested 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS). Vantage Invest Limited Liability Company holds 0.01% or 3,252 shares. Prelude Management Limited Liability Corp reported 48,891 shares or 0.03% of all its holdings. Moreover, Guggenheim Capital has 0% invested in Codexis, Inc. (NASDAQ:CDXS). Moreover, Nantahala Capital Management Limited Com has 2.48% invested in Codexis, Inc. (NASDAQ:CDXS) for 6.68 million shares. Strs Ohio invested in 0% or 88,800 shares. Rhumbline Advisers holds 0% or 35,893 shares. Legal General Gp Public Limited Company has 9,457 shares. Burney has 20,000 shares. Bnp Paribas Arbitrage reported 0% stake.

Since March 21, 2018, it had 0 insider purchases, and 5 selling transactions for $1.19 million activity. BARUCH THOMAS R also sold $276,318 worth of Codexis, Inc. (NASDAQ:CDXS) on Wednesday, March 28. WOLF DENNIS P sold $464,384 worth of stock. On Tuesday, April 3 Smith David V sold $62,213 worth of Codexis, Inc. (NASDAQ:CDXS) or 6,000 shares. Shares for $259,828 were sold by NICOLS JOHN J on Thursday, March 22.

Why Has Stephens Given Codexis (NASDAQ:CDXS) a $16.0000 Price Target

In a research report made public on Wednesday, 16 May, stock research analysts at Stephens has initiated coverage for Codexis (NASDAQ:CDXS) shares. The firm has decided to set a “Buy” rating along with a $16.0000, adding 14.70 % to the target.

The stock increased 5.28% or $0.7 during the last trading session, reaching $13.95. About 602,084 shares traded or 43.64% up from the average. Codexis, Inc. (NASDAQ:CDXS) has risen 125.77% since May 17, 2017 and is uptrending. It has outperformed by 114.22% the S&P500.

Analysts await Codexis, Inc. (NASDAQ:CDXS) to report earnings on August, 8. They expect $-0.03 EPS, up 76.92 % or $0.10 from last year’s $-0.13 per share. After $-0.10 actual EPS reported by Codexis, Inc. for the previous quarter, Wall Street now forecasts -70.00 % EPS growth.

Codexis, Inc. discovers, develops, and sells protein catalysts. The company has market cap of $742.70 million. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable clients to perform chemistry screening. It currently has negative earnings. The firm also provides protein catalyst screening and protein engineering services.

More important recent Codexis, Inc. (NASDAQ:CDXS) news were published by: Globenewswire.com which released: “Codexis Reports First Quarter 2018 Financial Results” on May 10, 2018, also Seekingalpha.com published article titled: “Codexis’ (CDXS) CEO John Nicols on Q1 2018 Results – Earnings Call Transcript”, Nasdaq.com published: “3 High-Growth Stocks That Are Just Getting Started” on May 12, 2018. More interesting news about Codexis, Inc. (NASDAQ:CDXS) was released by: Globenewswire.com and their article: “Codexis to Hold First Quarter 2018 Conference Call on May 10” with publication date: May 03, 2018.

Codexis, Inc. (NASDAQ:CDXS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: